실외 알레르기비염의 원인, 증상 및 완화

1. Center for Disease Control and Prevention, Editors. Allergies and Hay Fever, Center for Disease Control and Prevention (cdc.gov), 2018. Reviewed on Oct. 5, 2021.

2. Andrew Moore, MD, Reviewed. Outdoor Allergens, American Academy of Allergy, Asthma & Immunology (aaaai.org), September 28, 2020. Reviewed on Oct. 5, 2021.

3. Andrew Moore, MD, Reviewed. Seasonal Allergies, American Academy of Allergy, Asthma & Immunology [acaai.org], December 28, 2017. Reviewed on Oct. 5, 2021.

4. Andrew Moore, MD, Reviewed. Indoor Allergens, American Academy of Allergy, Asthma & Immunology [aaaai.com], February 28, 2020. Reviewed on Oct. 5, 2021.

5. Jonathan Corren, MD. Allergic rhinitis: Treating the adult, The Journal of Allergy and Clinical Immunology, June 1, 2000. Reviewed on Oct. 5, 2021.

6. NIH Medline Plus Magazine, Editors. What triggers seasonal allergies?, NIH Medline Plus Magazine (magazine.medlineplus.gov),2020

7. Olasińska-Wiśniewska A, et al. Cardiovascular safety of antihistamines. Postępy Dermatologii i Alergologii. 2014.31(3);182-186

8. Bousquet J et al. Allergic Rhinitis. Nat Rev Dis Primers. 2020.6(95);1-17

9. Mark E et al. Efficacy and tolerability of 2nd and 3rd gen antihistamines. ANNALS OF ALLERGY, ASTHMA & IMMUNOL. 2010.104;518–522

10. Fein MN et al. CSACI position statement_Newer generation H1-antihistamines (3rd generation) are safer than first-generation H1-antihistamines. Allergy Asthma Clin Immunol. 2019.15(61);1-6

11. Anne K et al. Second-and third-generation antihistamines. DERMATOLOGIC THERAPY. 2000.13;327–336

12. Thomas B et al. Next generation antihistamines therapeutic rationale accomplishments and advances. Expert Opinion on Investigational Drugs. 2002.11(6);807-817

13. Day J H et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride. Ann Allergy Asthma Immunol. 1997.79;533-540.

14. Smith SM et al. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opinion on Drug Metabolism & Toxicology. 2009;5(7);813-22

15. Peter H. Double-blind, placebo-controlled study. Comparing the efficacy and safety of fexofenadine and cetirizine in seasonal AR. J ALLERGY CLIN IMMUNOL. 1999;104(5);927-33

16. Van Cauwenberge et al. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg. Clin Exp Allergy. 2000. 30(6);891-899

[Study Design¹³] This study was of a randomized, placebo-controlled, double-blind, parallel design. The purpose of this study was to characterize the time to onset of clinically important relief of symptoms of allergic rhinitis in subjects taking single doses of either 60 mg or 120 mg fexofenadine HCl, or placebo, after exposure to ragweed pollen in a controlled environment. Other objectives were to assess the efficacy and safety of single doses of fexofenadine HCl.

[Study Design¹⁵] A multicenter, double-blind, parallel-group, placebo-controlled trial compared the efficacy and safety of fexofenadine HCl (120 and 180 mg administered once daily) and cetirizine (10 mg once daily) in the treatment of seasonal allergic rhinitis. The primary efficacy variable was the change in mean 24-hour reflective TSS during the treatment period in relation to the single blind placebo lead-in phase.

[Study Design¹⁶] This was a multinational, multicentre, double-blind, parallel group, randomized, placebo-controlled study. Following a placebo run-in phase of 3±7 days (the baseline period) patients with SAR were randomized to receive one capsule of either fexofenadine HCl 120mg(n=232), loratadine 10mg(n=228), or placebo(n=225), once each morning for 14 days. The primary efficacy parameter was the change in the mean 24-h reflective TSS during the double blind treatment period from that during the baseline period.